Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 30;11(7):1183. doi: 10.3390/vaccines11071183

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Frequency of individuals producing anti-RBD IgA according to post-vaccine collection periods. The frequency of individuals producing anti-RBD IgA was evaluated by means of the enzyme immunoassay (ELISA) described in the methods section. This analysis was carried out for post-vaccine collections at T2: 1 month after application of the second dose (A), T3: 4–6 months after application of the second dose or pre-third dose (B), and T4: 1 month after application of the third dose (C) by comparison between vaccine groups. The results are expressed in percentage. Fisher’s exact test was used for comparison of antibody response between groups. Statistical significance was adopted for p < 0.05.